A quiet crisis is unfolding across America, one that forces agonizing choices upon families. It’s not a new disease, but a soaring cost: insulin. For millions living with diabetes, this life-sustaining medication is becoming increasingly unaffordable, pushing some to dangerously ration their doses.
Now, a bipartisan coalition in the Senate is attempting to break through years of stalemate with a renewed push for the INSULIN Act of 2026. The legislation aims to cap monthly insulin costs at $35 for most Americans with insurance, a lifeline for those struggling to keep up with rising prices.
The core of the bill focuses on eliminating deductibles for selected insulin products within group and individual health plans. Starting in 2027, a 30-day supply would be capped at $35, with further reductions planned for 2028, ensuring patients pay no more than $35 or 25% of the negotiated net price – whichever is lower.
This isn’t a new fight. A $35 Medicare cap was already established in 2022, but the struggle extends to the millions covered by private insurance. Senators Jeanne Shaheen, Susan Collins, Raphael Warnock, and John Kennedy are leading the charge, driven by a shared concern for their constituents.
Senator Collins recounted a recent, heartbreaking encounter: a young woman forced to jeopardize her health by stretching her insulin supply, simply because she couldn’t afford the full prescription. Stories like hers fuel the urgency behind this legislation.
The bill also addresses a critical gap – the uninsured. Recognizing that many fall through the cracks, it proposes a five-year pilot program in ten states, offering insulin at no more than $35 a month to those without insurance coverage.
The effort gains unexpected momentum from a familiar voice: former President Trump. His previous focus on lowering prescription drug costs, including a “Most Favored Nation” policy aimed at securing lower prices for Americans, creates a surprising alignment on this issue.
Trump’s initiatives, including agreements with pharmaceutical companies and a new prescription drug portal offering insulin at $25, demonstrate a commitment to affordability. This bipartisan support offers a rare opportunity for progress.
Beyond capping costs, the INSULIN Act tackles the underlying drivers of high prices. It targets pharmacy benefit manager practices and seeks to encourage competition from biosimilar and generic insulin products, aiming for long-term, systemic change.
A federal study will also be commissioned to investigate delays in bringing new insulin products to market and identify barriers to the adoption of more affordable biosimilars. The goal is to streamline the process and increase access to cheaper alternatives.
While the bill has been reworked and refined, the path forward remains challenging. Securing buy-in from Senate leadership and attaching it to must-pass legislation will be crucial. But after years of setbacks, advocates believe a bipartisan framework for meaningful change is finally within reach.
For Senator Shaheen, who is nearing the end of her Senate career, this legislation represents a final opportunity to leave a lasting legacy. “I would really like to be able to leave the Senate thinking that we had helped to address insulin costs for a lot of Americans,” she stated, recognizing diabetes as “the most expensive chronic disease.”
